Chronic Lymphocytic Leukemia (CLL) demonstrates variable reactivity of the B cell receptor 
Bruton's Tyrosine Kinase (BTK) Function is Important to the Development and Expansion of Chronic Lymphocytic Leukemia (CLL)
Introduction CLL is a common adult leukemia that is currently incurable outside of stem cell transplantation.
Though response to IgM ligation is variable, the B cell receptor (BCR) signaling pathway is aberrantly active in this disease, with antigen-dependent 1, 2 or independent autonomous activation 3 leading to constitutive activation of kinases inducing cell survival and proliferation. [4] [5] [6] [7] One BCR pathway kinase that is uniformly over-expressed at the transcript level 8 and constitutively phosphorylated in CLL is Bruton's tyrosine kinase (BTK). Ibrutinib, an orally bioavailable irreversible inhibitor of BTK, has recently been shown to have outstanding clinical activity in CLL with extended durable remissions in both untreated and relapsed disease.
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BTK is a critical mediator of B lymphocyte signaling and development. Mutations in various domains are responsible for X-linked agammaglobulinemia (XLA), 10, 11 a disorder characterized by developmental arrest of B cells and profound humoral immune deficiency in humans. A point mutation in the PH domain is responsible for the milder X-linked immunodeficiency (XID) phenotype in the mouse 12, 13 which is characterized by reduced numbers of circulating B cells and reduced serum immunoglobulins. BTK is also a critical mediator in B cell signaling. It is recruited to the membrane-bound signalosome in the early stages of B cell activation, and, following phosphorylation by Syk and Lyn, participates in the phosphorylation of PLCγ2 which leads to production of the second messengers diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3). This pathway is amplified in CLL and leads to pro-survival signals through its effects on PI3K, PLCγ2, and NFkB. 5, 8, 14, 15 16, 17 Ibrutinib has been shown to inhibit microenvironment survival signals and block the protective effect of stromal co-culture in vitro. 8 It is apparent that BTK is critical for the development and function of normal B lymphocytes, and protein expression appears to be required for CLL development. 18 However, the precise role of the kinase function of BTK in the initial development of CLL as well as the disease expansion phase is unclear. In addition, the concept of targeting a specific protein kinase in CLL, similar to targeting BCR-Abl in chronic myeloid leukemia, is one not generally believed to be feasible in CLL. Indeed, the lack of a ubiquitously amplified or mutated protein and overall heterogeneity of the disease suggests that multiple pathways would need to be targeted to achieve disease The work outlined below will demonstrate that BTK is an important target in CLL and likely the critical kinase targeted by ibrutinib, and will thus validate BTK as a target for future drug development.
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Materials and Methods

CLL patient samples
Blood samples were collected from patients that satisfied standard morphologic and immunophenotypic criteria for B cell CLL. Informed consent was obtained from all patients according to the Declaration of Helsinki and approval for the study was obtained from the institutional human research committee at the Catholic University Hospital "A. Gemelli". Nucleofections were performed on 6-8x10 6 CLL cells using Nucleofector Solution V, the Amaxa Nucleofector II device and the U-013 program (Amaxa Biosystems GmbH, Cologne-Germany).
Following nucleofection, CLL cells were resuspended at a cell density of 1x10 7 /mL in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, 0.1 mg/mL streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate (Invitrogen, Carlsbad, CA Table 1 ).
Mouse flow cytometry
Flow cytometry to determine peripheral blood leukemia involvement was performed by staining fresh whole blood with anti-mouse CD45 APC, anti-mouse CD5 FITC, and anti-mouse CD19 PE (all from BD Biosciences, Franklin Lakes, NJ). CountBright beads were obtained from
Invitrogen and used according to manufacturer's instructions. Cells were initially doubletdiscriminated, and then gated on the CD45 positive population. Flow cytometry was performed on a Beckman-Coulter FC-500 flow cytometer, and Kaluza software was used for data analysis.
Mouse immunoblot analysis
Whole cell lysates were prepared as previously described by our group. 24 Equivalent amounts of protein were loaded into polyacrylamide gels and transferred onto nitrocellulose membranes.
Following antibody incubations, proteins were detected with chemiluminescent substrate (SuperSignal, Pierce, Rockford, IL). pErk antibody was obtained from Millipore (Billerica, MA),
Erk antibody was obtained from Cell Signaling Technology (Beverly, MA), and Actin antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Statistical Methods
Percent viability of CLL cells measured under different conditions are summarized with means
and standard deviations and compared using paired t-tests. For the mouse models, estimates of leukemia-free survival, overall survival, and time to engraftment were obtained using the Kaplan-Meier method and the log-rank test evaluated differences between curves. Leukemia- 8 Collectively, these studies point toward the potential importance of this kinase in human CLL.
As we have seen that BTK knockdown leads to decreased CLL cell viability, we sought to determine whether the BTK kinase is a viable target in CLL in vivo. To evaluate this we utilized the well characterized TCL1 mouse model which has been shown to possess genetic, epigenetic, and pharmacologic properties of human CLL. 20, 25 B6/TCL1 mice were crossed with the well characterized XID mouse which has a point mutation in BTK preventing PH domain binding and therefore kinase activity. Table 1 , Supplemental Figure 5 ). BCR signaling, using phosphorylation of ERK as a surrogate, is inhibited in these mice (Supplemental Figure 2) .
From the time of leukemia diagnosis, mice treated with ibrutinib survived significantly longer (46 versus 24 days, p=0.003) with ibrutinib as compared to vehicle (Figure 3) . Unlike human CLL, in this model no lymphocytosis was observed after treatment with ibrutinib. These data confirm that ibrutinib is effective in transplanted primary TCL1 leukemia cells not selected for enhanced BCR signaling and also that this drug inhibits the expansion phase of CLL in this model.
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We next sought to determine whether inhibition of BTK kinase function by ibrutinib can prevent CLL development similar to that observed in XID/TCL1 mice outlined above. Figure 4B ). This confirms that ibrutinib treatment inhibits the development of TCL1 leukemia similar to genetic inactivation of BTK.
Discussion
Collectively, our data show that kinase-functional BTK is critical to the development and expansion of CLL. While the inhibition in disease expansion demonstrated by the survival advantage in established disease is expected given the dramatic responses to this drug seen in the clinic, more remarkable is the significant delay in leukemia onset after targeted inactivation of BTK through either the XID/TCL1 model or the administration of ibrutinib. The XID/TCL1 cross definitively demonstrates that BTK is an important kinase in CLL, and the similar results seen with the BTK inhibitor ibrutinib suggest that this is the most relevant target of ibrutinib in CLL. While our data do not rule out the contribution of other related kinases to the efficacy of ibrutinib in patients, it does provide further support that BTK is indeed an important target of the drug.
The efficacy that has been seen with ibrutinib has led to preliminary development of more 
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